Retatrutide affects three key hormonal receptors — GLP-1R, GIPR, and GCGR — making it a novel investigational triple receptor agonist developed by Eli Lilly. This triple mechanism sets it apart from currently approved medicines such as semaglutide (a GLP-1R monoagonist) and tirzepatide (a GLP-1R/GIPR dual agonist). By simultaneously targeting all three receptors, retatrutide is hypothesised to deliver additive effects on appetite suppression, insulin secretion, and energy expenditure. This article explains what each receptor does, how retatrutide compares with approved therapies, and what UK patients should know about its current regulatory and clinical development status.

The Three Receptors Targeted by Retatrutide

Retatrutide targets three receptors: GLP-1R, GIPR, and GCGR. This triple agonism distinguishes it from approved dual agonists such as tirzepatide and monoagonists such as semaglutide.

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that simultaneously targets three distinct hormonal receptors involved in energy regulation and metabolic control. Understanding which three receptors retatrutide affects is central to appreciating its pharmacological rationale in obesity and metabolic medicine.

The three receptors targeted by retatrutide are:

• GLP-1R (Glucagon-like peptide-1 receptor) — a well-established target already exploited by approved medicines such as semaglutide and liraglutide

• GIPR (Glucose-dependent insulinotropic polypeptide receptor) — also targeted by tirzepatide in combination with GLP-1R

• GCGR (Glucagon receptor) — an additional target that distinguishes retatrutide from currently approved dual agonists

This triple mechanism of action places retatrutide in a distinct pharmacological class. By engaging all three receptors concurrently, the drug is hypothesised to produce additive or synergistic effects on appetite suppression, insulin secretion, and energy expenditure — though this remains to be confirmed in ongoing phase 3 trials. Each receptor plays a distinct physiological role, and their combined activation is under investigation as a means of delivering improved metabolic outcomes compared with single or dual agonism alone.

Retatrutide remains under clinical investigation and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom.

How Each Receptor Contributes to Weight Loss and Metabolism

GLP-1R reduces appetite and improves glycaemic control; GIPR enhances insulin secretion and may improve insulin sensitivity; GCGR activation is hypothesised to increase energy expenditure and hepatic fat oxidation, though evidence remains largely preclinical.

Each of the three receptors targeted by retatrutide is thought to contribute to weight loss and metabolic improvement through distinct but potentially complementary pathways. The mechanisms described below reflect current scientific understanding, including data from the 2023 phase 2 trial published in the New England Journal of Medicine (NEJM), as well as preclinical and mechanistic research; several aspects remain under active investigation.

GLP-1 receptor activation slows gastric emptying, reduces appetite by acting on hypothalamic satiety centres, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. These effects reduce caloric intake and improve glycaemic control — mechanisms already validated in approved medicines such as semaglutide (Ozempic®, Wegovy®) and liraglutide (Victoza®, Saxenda®).

GIP receptor activation enhances insulin secretion in a glucose-dependent manner and may improve insulin sensitivity in adipose tissue. It has been hypothesised, based largely on data from tirzepatide studies, that GIPR agonism may moderate some of the gastrointestinal side effects associated with GLP-1R stimulation; however, human evidence for this effect remains limited and mixed, and it should be regarded as an area of ongoing research rather than established fact. Tirzepatide (Mounjaro®), licensed in the UK by the MHRA, demonstrates the clinical benefit of combining GLP-1R and GIPR agonism.

Glucagon receptor activation is the distinguishing feature of retatrutide. Glucagon traditionally raises blood glucose by stimulating hepatic glucose output. However, based on preclinical data and early human trial findings, glucagon receptor co-activation in the context of concurrent GLP-1R and GIPR agonism is hypothesised to:

• Increase energy expenditure, potentially by promoting thermogenesis

• Enhance hepatic fat oxidation, which may reduce liver fat content

• Contribute to appetite suppression through central nervous system pathways

These GCGR-mediated mechanisms are largely derived from preclinical and indirect human data and require confirmation in larger trials. In the phase 2 NEJM 2023 trial, the net glycaemic effect of retatrutide was favourable — improvements in fasting glucose and insulin resistance markers were observed — suggesting that the insulin-stimulating effects of GLP-1R and GIPR agonism counterbalanced any glucose-raising tendency from glucagon receptor activation. Nevertheless, the theoretical risk of hyperglycaemia from glucagon signalling remains a consideration in ongoing research.

Retatrutide Compared to Other Multi-Receptor Agonists

Retatrutide's addition of GCGR agonism to GLP-1R and GIPR targeting distinguishes it from tirzepatide and semaglutide; phase 2 data are promising but phase 3 confirmation is required before any superiority claims can be made.

To contextualise retatrutide's profile, it is helpful to compare it with other incretin-based therapies currently available or in development. The landscape of receptor agonism in metabolic medicine has evolved rapidly over the past decade.

Semaglutide (a GLP-1R monoagonist) achieved mean weight reductions of approximately 15–17% in the STEP clinical trial programme (STEP-1, NEJM 2021). Tirzepatide (a GLP-1R/GIPR dual agonist), licensed by the MHRA as Mounjaro® for type 2 diabetes and, subject to NICE guidance, for weight management in adults with obesity, achieved mean weight reductions of up to approximately 22% in the SURMOUNT-1 trial (NEJM 2022) — a notable improvement over GLP-1R monotherapy.

Retatrutide, as a triple agonist (GLP-1R + GIPR + GCGR), is hypothesised to build on these benchmarks by adding the thermogenic and lipolytic effects attributed to glucagon receptor activation. In the phase 2 NEJM 2023 trial, mean weight reductions of up to approximately 24% were observed at the highest dose (12 mg) over 48 weeks. These figures are promising but require confirmation in the ongoing phase 3 TRIUMPH programme before any conclusions about superiority over approved agents can be drawn.

Key distinctions between these agents include:

• Receptor breadth: Retatrutide's inclusion of GCGR agonism is unique among agents in advanced clinical development

• Hepatic effects: The glucagon component is under investigation for potential benefit in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD); this remains investigational and does not represent an approved or established indication

• Tolerability profile: Whether retatrutide's gastrointestinal side effect burden differs meaningfully from dual agonists cannot be determined without head-to-head comparative data

Retatrutide is not approved in the UK. Patients should not attempt to access it outside of regulated clinical trial settings.

Clinical Evidence and Trial Findings from Current Research

The key phase 2 trial (NEJM, 2023) reported mean weight reductions of up to approximately 24.2% at the highest dose over 48 weeks; phase 3 TRIUMPH trials are ongoing and required before regulatory submission.

The clinical evidence base for retatrutide is still maturing. The most significant data to date come from a phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023). This trial enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and evaluated multiple doses of retatrutide against placebo over 48 weeks.

Key findings from this phase 2 obesity trial included:

• Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks

• Dose-dependent reductions in body weight across all active treatment arms

• Significant reductions in waist circumference, blood pressure, and lipid parameters

• Improvements in fasting glucose and insulin resistance markers

A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management. Full publication details for this trial should be verified against the primary source.

Phase 3 trials (the TRIUMPH programme, registered on ClinicalTrials.gov) are currently underway, evaluating retatrutide across broader populations including those with cardiovascular disease, type 2 diabetes, and obesity-related complications. These trials will be critical in determining whether the promising phase 2 signals translate into robust, long-term clinical outcomes and an acceptable safety profile sufficient for regulatory submission to bodies such as the MHRA and EMA. Until phase 3 data are available and regulatory review is complete, the full clinical picture remains incomplete.

Potential Side Effects Linked to Receptor Activity

The most common side effects in phase 2 trials were gastrointestinal, including nausea, vomiting, and diarrhoea, consistent with GLP-1R agonist class effects; glucagon receptor activation carries a theoretical hyperglycaemia risk, though phase 2 data suggest this is counterbalanced.

As with all incretin-based therapies, retatrutide's side effect profile is closely linked to its receptor pharmacology. The following reflects current understanding based on phase 2 data and the established safety profiles of approved GLP-1 receptor agonists per UK Summary of Product Characteristics (SmPCs).

GLP-1 receptor-mediated effects are the most well-characterised and include:

• Nausea, vomiting, and diarrhoea — typically dose-dependent and most prominent during dose escalation

• Reduced appetite and early satiety

• Pancreatitis has been reported with GLP-1 receptor agonist class medicines; patients should seek prompt medical attention if they develop severe or persistent abdominal pain

• Gallbladder-related disorders (including cholelithiasis) are a recognised class effect of GLP-1 receptor agonists, as reflected in UK SmPCs for semaglutide and liraglutide

• Animal studies with GLP-1 receptor agonists have identified thyroid C-cell changes in rodents; the relevance to humans is unknown. UK SmPCs advise that patients should report any symptoms such as a neck lump, hoarseness, or difficulty swallowing to their doctor

GIP receptor-mediated effects are not yet fully characterised in humans. It has been hypothesised that GIPR agonism may moderate GLP-1-associated nausea, but this remains under investigation and should not be regarded as established.

Glucagon receptor-mediated effects introduce additional considerations:

• Potential for transient increases in heart rate (also observed with GLP-1R agonists)

• Theoretical risk of hyperglycaemia from glucagon signalling, though phase 2 trial data suggest this is counterbalanced by concurrent GLP-1R and GIPR agonism

In phase 2 trials, the most commonly reported adverse events were gastrointestinal in nature, consistent with the class. Nausea-related discontinuations occurred at higher doses.

Anyone experiencing severe abdominal pain, persistent vomiting, or other concerning symptoms should seek prompt medical advice. Suspected adverse reactions to any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What UK Patients Should Know About Retatrutide's Development

Retatrutide is not approved by the MHRA or EMA and cannot be legally prescribed or dispensed in the UK; patients interested in access should explore the NIHR Be Part of Research platform for legitimate clinical trial opportunities.

For patients in the United Kingdom who have heard about retatrutide — perhaps through media coverage of its early trial results — it is important to have a clear and balanced understanding of where this medicine currently stands in its development.

Retatrutide is not currently approved in the UK. It has not received a marketing authorisation from the MHRA or a positive opinion from the EMA. It is therefore not available through the NHS, private prescription, or any legitimate UK pharmacy. Patients should be cautious about any online sources claiming to supply retatrutide, as these are likely to be unregulated, counterfeit, or unsafe products.

For those interested in accessing retatrutide through legitimate means, clinical trial participation may be an option. The TRIUMPH phase 3 programme is recruiting internationally, and UK sites may be involved. Patients can search for registered trials via:

• NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) — the primary UK public-facing trial finder

• ClinicalTrials.gov — for international trial listings including TRIUMPH studies

• ISRCTN Registry (isrctn.com) — for UK-registered trials

Note that the EU Clinical Trials Register primarily covers trials registered in EU member states and may not list UK-based trials following the UK's departure from the EU.

In the meantime, UK patients with obesity or type 2 diabetes have access to several MHRA-licensed treatments supported by NICE guidance, including:

• Semaglutide (Wegovy® for weight management; Ozempic® for type 2 diabetes) — see NICE Technology Appraisal TA875

• Tirzepatide (Mounjaro®) — licensed by the MHRA for type 2 diabetes and, subject to applicable NICE guidance and local formulary decisions, for weight management in adults with obesity

• Liraglutide (Saxenda® for weight management; Victoza® for type 2 diabetes)

Availability of these treatments depends on local formulary decisions, NHS service pathways, and eligibility criteria set out in relevant NICE Technology Appraisals. Patients are encouraged to speak with their GP or a specialist weight management service about the most appropriate treatment for their individual circumstances. NICE guidance on obesity management (including CG189 and relevant Technology Appraisals) provides a framework for evidence-based care in the UK.

Retatrutide, if approved in future, would represent a potential addition to this landscape — but that determination rests on the outcome of ongoing phase 3 research and subsequent regulatory review by the MHRA and EMA.

Frequently Asked Questions